CN114947129A - 一种降尿酸的大叶菊苣白芷保健食品及其制备方法 - Google Patents
一种降尿酸的大叶菊苣白芷保健食品及其制备方法 Download PDFInfo
- Publication number
- CN114947129A CN114947129A CN202210590643.0A CN202210590643A CN114947129A CN 114947129 A CN114947129 A CN 114947129A CN 202210590643 A CN202210590643 A CN 202210590643A CN 114947129 A CN114947129 A CN 114947129A
- Authority
- CN
- China
- Prior art keywords
- parts
- angelica dahurica
- chicory
- raw materials
- big
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000213006 Angelica dahurica Species 0.000 title claims abstract description 104
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 235000013402 health food Nutrition 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 241000723343 Cichorium Species 0.000 title claims description 111
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 103
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 62
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 59
- 229940116269 uric acid Drugs 0.000 claims abstract description 59
- 239000002994 raw material Substances 0.000 claims abstract description 56
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 34
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 34
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 34
- 244000197580 Poria cocos Species 0.000 claims abstract description 34
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 34
- 240000008042 Zea mays Species 0.000 claims abstract description 34
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 32
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 32
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 32
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 32
- 235000005822 corn Nutrition 0.000 claims abstract description 32
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 31
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 31
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 31
- 235000011477 liquorice Nutrition 0.000 claims abstract description 31
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 31
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 235000013361 beverage Nutrition 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 241001342551 Macrophyllum Species 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 244000298479 Cichorium intybus Species 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 235000018927 edible plant Nutrition 0.000 abstract description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 32
- 201000005569 Gout Diseases 0.000 description 17
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 206010033425 Pain in extremity Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- BFFPVEVGHKMWLT-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurin-6-one Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 BFFPVEVGHKMWLT-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 230000006825 purine synthesis Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GWGLGTKSTGSWGQ-UPHRSURJSA-N (z)-4-(carbamoylamino)-4-oxobut-2-enoic acid Chemical compound NC(=O)NC(=O)\C=C/C(O)=O GWGLGTKSTGSWGQ-UPHRSURJSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 241000249820 Lipotes vexillifer Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007495 abnormal renal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降尿酸的大叶菊苣白芷保健食品及其制备方法,其中,降尿酸的大叶菊苣白芷保健食品,其原料按重量份数比包括:大叶菊苣30‑50份,白芷20‑25份,车前草10‑15份,玉米须10‑15份,茯苓5‑10份,甘草5‑10份,麦芽糊精5‑10份,硬脂酸镁5‑10份。本发明的保健食品经综合调配之后,具有降尿酸的效果,保健价值高。且本发明的主要原料都为药食同源的植物,在治疗期间内服用而无明显毒副作用。
Description
技术领域
本发明涉及保健食品技术领域,具体是一种降尿酸的大叶菊苣白芷保健食品及其制备方法。
背景技术
“高尿酸”是人体内有一种叫做嘌呤的物质因代谢发生紊乱,致使血液中尿酸增多而引起的一种代谢性疾病。在临床上,男性尿酸正常值:149~416umol/L;女性尿酸正常值:89~357umol/L。如果超出指标的话,就是高尿酸。高尿酸血症可分为原发性高尿酸血症及继发性高尿酸血症。
原发性高尿酸血症,有两个特点:一原因未明的分子缺陷;二先天性嘌呤代谢障碍。5-磷酸核苷酸-1-焦磷酸合成酶(PRPPS)活性增加,引起5-磷酸核苷酸-1-焦磷酸合成酶合成过多,尿酸产生过多,遗传特征为X连锁。次黄嘌呤-鸟嘌呤磷酸糖转移酶(HPRT)部分缺少,引起5-磷酸核苷酸-1-焦磷酸合成酶浓度增加,尿酸产生过多,遗传特征为X连锁。次黄嘌呤-鸟嘌呤磷酸糖转移酶完全缺乏,嘌呤合成增多所致的尿酸产生过多,见于Lesch-Nyhan综合征,遗传特征为X连锁。葡萄糖-6-磷酸酶缺乏,嘌呤合成增多所导致的尿酸产生过多和肾清除尿酸减少,见于糖原积累病I型,遗传特征为常染色体隐性遗传。
继发性高尿酸血症,是有多种急慢性疾病如血液病或恶性肿瘤、慢性中毒、药物或高嘌呤饮食所致的血尿酸产生增高或尿酸排泄障碍所致高尿酸血症。
形成高尿酸的原因受到多种因素的影响,与遗传、性别、年龄、生活方式有关,但主要有嘌呤类物质代谢异常和肾处理尿功能两个。嘌呤类物质代谢异常:如果人的体内嘌呤类物质代谢一旦发生异常,往往就会导致血液中尿酸的升高,人体内尿酸的来源不仅是外界饮食代谢,内源性嘌呤生成过多也是尿酸高的原因;肾处理尿功能异常:体内嘌呤物质新陈代谢紊乱致使尿酸排出量持续减少,较多的患者会有肾处理尿功能异常的现象。
高尿酸的临床表现:无症状高尿酸血症指患者仅有高尿酸血症(男性和女性血尿酸分别为>420μmol/L和360μmol/L)而无关节炎、痛风石、尿酸结石等临床症状。发病率在成年男性占5%~7%。患者不曾有过痛风关节炎发作,只是查体时,偶然发现血中尿酸值偏高。
高尿酸血症与痛风:高尿酸血症是痛风的发病基础,但不足以导致痛风,只有尿酸盐在机体组织中沉积下来造成损害才出现痛风;血尿酸水平越高,未来5年发生痛风的可能性越大。
高尿酸血症与高血压:多个流行病学研究证实,血尿酸是高血压发病的独立危险因素,血尿酸水平每增高59.5μmol/L,高血压发病相对危险增高25%。临床研究发现,原发性高血压患者90%合并高尿酸血症,而继发性高血压患者只有30%合并高尿酸血症,提示高尿酸血症与原发性高血压有因果关系。
高尿酸血症与糖尿病:长期高尿酸血症可破坏胰腺β细胞功能而诱发糖尿病,且有研究证实,长期高尿酸血症与糖耐量异常和糖尿病发病具有因果关系。
高尿酸血症与高甘油三酯血症:国内外的流行病学资料一致显示,血尿酸和甘油三酯之间有相关性。关于尿酸及甘油三酯关系的一项前瞻性队列研究发现,基础甘油三酯是未来高尿酸血症的独立预测因素。
高尿酸血症与代谢综合征:代谢综合征的病理生理基础是高胰岛素血症和胰岛素抵抗。胰岛素抵抗使糖酵解过程及游离脂肪酸代谢过程中血尿酸生成增加,同时通过增加肾脏对尿酸的重吸收直接导致高尿酸血症,代谢综合征患者中70%同时合并高尿酸血症。
高尿酸血症与冠心病:尿酸是冠心病死亡独立危险因素,有研究显示,无论性别,尿酸是普通人群冠心病死亡的独立危险因素,血尿酸每升高1mg/dl,死亡危险性在男性增高48%,女性增高126%。血尿酸>357μmol/L是冠心病的独立危险因素;血尿酸>416.5μmol/L是脑卒中的独立危险因素。
高尿酸血症与肾脏损害:尿酸与肾脏疾病关系密切,除尿酸结晶沉积导致肾小动脉和慢性间质炎症使肾损害加重以外,许多流行病学调查和动物研究显示,尿酸可直接使肾小球入球小动脉发生微血管病变,导致慢性肾脏疾病。
总之高尿酸能够引起高血脂高血压高血糖,引起动脉硬化,引起痛风疾病,会相继出现肾结石,尿蛋白,肾坏死,肾积水等恶性反应。
随着人们生活水平的提高,慢性病已经成为影响我国居民健康水平提高、阻碍经济社会发展的重大公共卫生问题和社会问题。根据近年各地高尿酸血症患病率的报道,目前我国约有高尿酸血症者1.2亿,约占总人口的10%,高发年龄为中老年男性和绝经后女性,但近年来有年轻化趋势,对于高尿酸患者,常需要使用药物成分进行尿酸控制。但是,是药三分毒,长期服药,这不可避免会对身体造成一定的危害。本申请提出一种降尿酸的大叶菊苣白芷保健食品,以解决上述问题。
发明内容
本发明的目的在于提供一种降尿酸的大叶菊苣白芷保健食品及其制备方法,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种降尿酸的大叶菊苣白芷保健食品,其原料按重量份数比包括:大叶菊苣30-50份,白芷20-25份,车前草10-15份,玉米须10-15份,茯苓5-10份,甘草5-10份,麦芽糊精5-10份,硬脂酸镁5-10份。
一种降尿酸的大叶菊苣白芷保健食品的制备方法,所述的大叶菊苣白芷保健食品为片剂,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-4次,每次30-40min,进行提纯,每次水的用量为上述原料的3-8倍;
S3、提纯3-4次后,合并提取液,提取液经过过滤浓缩、喷雾干燥后,得到药物浓缩干燥粉;
S4、将药物浓缩干燥粉与麦芽糊精、硬脂酸镁混合,经过制粒、干燥、压片,制得菊苣白芷片剂。
一种降尿酸的大叶菊苣白芷保健食品的制备方法,所述的大叶菊苣白芷保健食品为饮料,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-4次,每次30-40min,进行提纯,每次水的用量为上述原料的2-8倍;
S3、提纯3-4次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌后,制得菊苣白芷饮料,其中,浸膏在菊苣白芷饮料中的质量分数为10-15%。
一种降尿酸的大叶菊苣白芷保健食品的制备方法,所述的大叶菊苣白芷保健食品为口服液,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-5次,每次30-60min,进行提纯,每次水的用量为上述原料的2-10倍;
S3、提纯3-5次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌定容后,制得菊苣白芷口服液,其中,浸膏在菊苣白芷口服液中的质量分数为20-25%。
菊苣(Cichorium intybus L.),菊科菊苣属,多年生草本植物。菊苣为药食两用植物,叶可调制生菜,根含菊糖及芳香族物质,可提制代用咖啡,促进人体消化器官活动。植物的地上部分及根可供药用,中药名分别为菊苣、菊苣根,具有清热解毒,利尿消肿,对修复肾功能损伤,降尿酸等功效。
菊苣植物全草入药,味微苦、咸,性凉,归脾、肝、膀、胱经。菊苣中富含钾,能有效改善脑供氧,调节体内机能;大叶菊苣还含有特别成分,如小米皮素,对高体循环的动脉血压、高脂血症、高尿酸等疾病有明显的药用价值。
白芷,性温,味辛,气芳香,微苦。入肺、脾、胃经。白芷性质偏温,味道偏辛的药材,它的功效主要是散寒解表、祛风除湿,还有通窍的功效,对风寒感冒,头痛,眼睛痛,或者是像鼻塞以后引起的鼻周的肿痛,关节疼痛,或者是心绞痛,痛风等也有一定的功效。
车前草在本发明配方中的功效如下:性寒味甘。具有清热利尿功效,辅助大叶菊苣完善降尿酸的成分。
玉米须为禾本科植物玉蜀黍Zea maysL.的花柱和柱头。味甘、淡,性平。归膀胱、肝、胆经。古医书多有记载,《滇南本草》:宽肠下气,治妇人乳结,乳汁不通,红肿疼痛,怕冷发热,头痛体困;《民间常用草药汇编》:能降低血压,利尿消肿,治鼻血、红崩;《四川中药志》:清血热,利小便,治黄疸,风热,出疹,吐血及红崩;辅助大叶菊苣加强降尿酸的成分。
茯苓俗称云苓、松苓,为寄生在松树根上的菌类植物,其原生物为多孔菌科真菌茯苓的干燥菌核,茯苓性平,味甘淡,归心、肺、脾、肾经,是我国传统药材中非常重要的健脾利湿中药材,具体有利水消肿、健脾止泻、补益心脾、增强免疫功能等功效,协助大叶菊苣、白芷、玉米须、车前草加强降尿酸的作用。
甘草在本发明配方中的功效如下:性缓味甘,润肺,解毒,调和诸药,用于调和大叶菊苣、白芷、玉米须、车前草、茯苓诸药作用的成分。
与现有技术相比,本发明的有益效果是:本发明的保健食品经综合调配之后,具有降尿酸的效果,保健价值高。且本发明的主要原料都为药食同源的植物,在治疗期间内服用而无明显毒副作用。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一:一种降尿酸的大叶菊苣白芷保健食品,所述的大叶菊苣白芷保健食品为片剂,其原料按重量份数比具体包括:大叶菊苣38份,白芷22份,车前草12份,玉米须10份,茯苓7份,甘草10份,麦芽糊精8份,硬脂酸镁6份。
菊苣白芷片剂制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3次,每次30min,进行提纯,每次水的用量为上述原料的6倍;
S3、提纯3次后,合并提取液,提取液经过过滤浓缩、喷雾干燥后,得到药物浓缩干燥粉;
S4、将药物浓缩干燥粉与麦芽糊精、硬脂酸镁混合,经过制粒、干燥、压片,制得菊苣白芷片剂。
实施例二:一种降尿酸的大叶菊苣白芷保健食品,所述的大叶菊苣白芷保健食品为饮料,其原料按重量份数比具体包括:大叶菊苣35份,白芷20份,车前草15份,玉米须10份,茯苓8份,甘草8份,麦芽糊精5份,硬脂酸镁5份。
菊苣白芷饮料制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮4次,每次30min,进行提纯,每次水的用量为上述原料的8倍;
S3、提纯4次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌后,制得菊苣白芷饮料,其中,浸膏在菊苣白芷饮料中的质量分数为15%。
实施例三:一种降尿酸的大叶菊苣白芷保健食品,所述的大叶菊苣白芷保健食品为饮料,其原料按重量份数比具体包括:大叶菊苣30份,白芷20份,车前草10份,玉米须10份,茯苓5份,甘草5份,麦芽糊精5份,硬脂酸镁5份。
本实施例的菊苣白芷饮料制备方法与实施例二相同。
实施例四:一种降尿酸的大叶菊苣白芷保健食品,所述的大叶菊苣白芷保健食品为口服液,其原料按重量份数比具体包括:大叶菊苣38份,白芷20份,车前草10份,玉米须10份,茯苓8份,甘草10份,麦芽糊精5份,硬脂酸镁5份。
菊苣白芷口服液的制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮5次,每次30min,进行提纯,每次水的用量为上述原料的8倍;
S3、提纯5次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌定容后,制得菊苣白芷口服液,其中,浸膏在菊苣白芷口服液中的质量分数为25%。
实施例五:一种降尿酸的大叶菊苣白芷保健食品,所述的大叶菊苣白芷保健食品为口服液,其原料按重量份数比具体包括:大叶菊苣50份,白芷25份,车前草15份,玉米须15份,茯苓10份,甘草10份,麦芽糊精10份,硬脂酸镁10份。
本实施例的菊苣白芷口服液制备方法与实施例四相同。
实施案例:
菊苣白芷片剂的治疗使用方法:每次5-10克菊苣白芷片剂,一日两次,饭前饭后皆可服用,饭前效果更佳,每周吃五天休息两天,服用期间应多喝水,一个月为一个疗程;18周岁以下,哺乳期妇女及婴幼儿,对本发明主要原料过敏人员不宜服用。
菊苣白芷饮料的治疗使用方法:参考菊苣白芷片剂中有效成分(药物浓缩干燥粉)的含量,进行服用。
菊苣白芷口服液的治疗使用方法:参考菊苣白芷片剂中有效成分(药物浓缩干燥粉)的含量,进行服用。
病例一:2020年11月16日,邢某某,男,29岁,此患者饮食失调,喜食饮料和外卖,尿酸偏高,服用菊苣白芷片剂6个月之后,尿酸指标有了明显的降低。
病例二:2020年12月1日,汤某,男,43岁,该患者长期熬夜,基本以油炸食品为主食,爱喝啤酒,因为腿疼去医院检查确诊为痛风,服用菊苣白芷片剂8个月之后,痛风的症状明显减轻。
病例三:2020年12月9日,白某,男,23岁,该患者饮食不规律,长期的饮料和油炸食品,经常感觉腿疼,但是一直没有放在心上,体检时发现尿酸偏高,服用菊苣白芷片剂3个月之后,腿疼的症状基本没有了。
病例四:2020年12月15日,瞿某某,女,47岁,该患者曾做过乳腺切除手术,因为长期服用药物,导致肝肾功能的损伤,尿酸偏高,服用菊苣白芷片剂4个月之后,尿酸的检查指标有了很大的改变。
病例五:2020年12月21日,王某某,男,21岁,因为饮食不节制,加上缺乏运动,长期的久坐,导致体重居高不下,患上了肥胖症,经常感到脚疼,无法走路,后确诊痛风,严重时就到医院去挂水来缓解疼痛,调整生活方式后,服用菊苣白芷片剂4个月,尿酸的检查指标有了降低,服用7个月后,脚疼的症状基本消失。
病例六:2021年12月4日,刘某某,男,40岁,突然感觉四肢疼痛的厉害,尤其是关节处,连续几天都是如此,实在疼痛难忍就去医院检查,发现尿酸已经严重超出了正常的指标范围,服用菊苣白芷片剂3个月,四肢疼痛的频率开始减少,这也给了患者很大的信心,继续服用5个月后,这种疼痛的感觉基本没有了,尿酸的指标也恢复到正常范围。
病例七:2020年12月20日,孙某,女,60岁,患有高血脂症,长期服用降脂药,对自身的肝肾功能损伤很大,体检时发现尿酸偏高,开始服用菊苣白芷片剂,一个周期后,尿酸指标明显降低。
病例八:2020年12月28日,陈某某,男,48岁,长期饮酒,抽烟,喜食动物内脏等含嘌呤较高的食物,引起嘌呤代谢出现问题,出现了痛风性关节炎,调整生活方式后,加上服用服用菊苣白芷片剂3个月后,痛风的症状大大减轻。
病例九:2021年1月6日,王某某,男,65岁,服用降压药14年,对肾脏造成了不可挽回的损伤,同时也引发了尿酸的增高,服用菊苣白芷片剂5个月后,尿酸已经恢复正常指标。
病例十:2021年1月10日,曹某某,女,55岁,患糖尿病多年,长期服用降糖药,经常感到腿疼,刚开始以为是糖尿病的并发症,后来检查发现尿酸指标偏高,开始服用菊苣白芷片剂,3个月后指标有了很大的变化。
病例十一:2021年2月16日,石某,男,34岁,患有痛风已有两年的时间,长期抽烟饮酒,饮食不规律,服用菊苣白芷片剂的同时,调整生活方式,平时多喝水,6个月后,痛风基本没有再发作。
病例十二:2021年2月20日,单某某,男,40岁,饱受痛风折磨已经有了5年时间,四处求医吃药,偶然的机会开始服用菊苣白芷片剂,4个月后反馈痛风的症状已经大大减轻了,继续服用4个月,尿酸指标也逐步恢复正常的范围。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
Claims (9)
1.一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比包括:大叶菊苣30-50份,白芷20-25份,车前草10-15份,玉米须10-15份,茯苓5-10份,甘草5-10份,麦芽糊精5-10份,硬脂酸镁5-10份。
2.根据权利要求1所述的一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比具体包括:大叶菊苣30份,白芷20份,车前草10份,玉米须10份,茯苓5份,甘草5份,麦芽糊精5份,硬脂酸镁5份。
3.根据权利要求1所述的一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比具体包括:大叶菊苣38份,白芷22份,车前草12份,玉米须10份,茯苓7份,甘草10份,麦芽糊精8份,硬脂酸镁6份。
4.根据权利要求1所述的一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比具体包括:大叶菊苣35份,白芷20份,车前草15份,玉米须10份,茯苓8份,甘草8份,麦芽糊精5份,硬脂酸镁5份。
5.根据权利要求1所述的一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比具体包括:大叶菊苣38份,白芷20份,车前草10份,玉米须10份,茯苓8份,甘草10份,麦芽糊精5份,硬脂酸镁5份。
6.根据权利要求1所述的一种降尿酸的大叶菊苣白芷保健食品,其特征在于,其原料按重量份数比具体包括:大叶菊苣50份,白芷25份,车前草15份,玉米须15份,茯苓10份,甘草10份,麦芽糊精10份,硬脂酸镁10份。
7.根据权利要求1-6任一所述的一种降尿酸的大叶菊苣白芷保健食品的制备方法,其特征在于,所述的大叶菊苣白芷保健食品为片剂,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-4次,每次30-40min,进行提纯,每次水的用量为上述原料的3-8倍;
S3、提纯3-4次后,合并提取液,提取液经过过滤浓缩、喷雾干燥后,得到药物浓缩干燥粉;
S4、将药物浓缩干燥粉与麦芽糊精、硬脂酸镁混合,经过制粒、干燥、压片,制得菊苣白芷片剂。
8.根据权利要求1-6任一所述的一种降尿酸的大叶菊苣白芷保健食品的制备方法,其特征在于,所述的大叶菊苣白芷保健食品为饮料,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-4次,每次30-40min,进行提纯,每次水的用量为上述原料的2-8倍;
S3、提纯3-4次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌后,制得菊苣白芷饮料,其中,浸膏在菊苣白芷饮料中的质量分数为10-15%。
9.根据权利要求1-6任一所述的一种降尿酸的大叶菊苣白芷保健食品的制备方法,其特征在于,所述的大叶菊苣白芷保健食品为口服液,其制备方法包括如下步骤:
S1、按重量份数比称取精选的大叶菊苣、白芷、车前草、玉米须、茯苓、甘草、麦芽糊精、硬脂酸镁上述原料;
S2、将大叶菊苣、白芷、车前草、玉米须、茯苓、甘草上述原料用净水洗净,用水煮3-5次,每次30-60min,进行提纯,每次水的用量为上述原料的2-10倍;
S3、提纯3-5次后,合并提取液,并过滤,将滤液浓缩至在40-80℃下相对密度为1.00-1.10的浸膏;
S4、将上述浸膏与麦芽糊精、硬脂酸镁混合,然后,加入超纯水至100%,混合均匀、灭菌定容后,制得菊苣白芷口服液,其中,浸膏在菊苣白芷口服液中的质量分数为20-25%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210590643.0A CN114947129A (zh) | 2022-05-27 | 2022-05-27 | 一种降尿酸的大叶菊苣白芷保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210590643.0A CN114947129A (zh) | 2022-05-27 | 2022-05-27 | 一种降尿酸的大叶菊苣白芷保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114947129A true CN114947129A (zh) | 2022-08-30 |
Family
ID=82958508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210590643.0A Withdrawn CN114947129A (zh) | 2022-05-27 | 2022-05-27 | 一种降尿酸的大叶菊苣白芷保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114947129A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115518132A (zh) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | 高血尿酸症防治中药复方组合物 |
-
2022
- 2022-05-27 CN CN202210590643.0A patent/CN114947129A/zh not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115518132A (zh) * | 2022-10-24 | 2022-12-27 | 北京擎天数康科技有限公司 | 高血尿酸症防治中药复方组合物 |
WO2024087259A1 (zh) * | 2022-10-24 | 2024-05-02 | 北京擎天数康科技有限公司 | 一种防治高血尿酸症的中药复方组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN111588042A (zh) | 一种辅助降低尿酸和控制痛风的膳食营养调理食品 | |
CN109400750B (zh) | 一种具有降尿酸作用的药物组合物 | |
CN114947129A (zh) | 一种降尿酸的大叶菊苣白芷保健食品及其制备方法 | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
CN103977390B (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
CN106070783A (zh) | 一种薏米祛湿茶的生产工艺 | |
KR101391647B1 (ko) | 항비만 조성물 | |
KR20210075041A (ko) | 생약재 추출물 | |
KR20050023118A (ko) | 숙취해소 및 간기능 개선용 조성물 | |
KR20180056199A (ko) | 모링가추출물을 함유한 다이어트용 껌의 제조방법 | |
KR100642801B1 (ko) | 한약재와 배 추출물을 배합한 항당뇨 식품 조성물 및 그의제조방법 | |
CN110448579A (zh) | 一种快速降尿酸配方 | |
CN109662314A (zh) | 一种辅助降血糖、降血脂的复方湖北海棠叶功能性食品及其制备方法 | |
CN108030835A (zh) | 一种快速治疗牙龈肿痛的中药及其制作方法 | |
CN107998230A (zh) | 一种治疗牙龈肿痛的中药及其制作方法 | |
CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
KR102203094B1 (ko) | 천연물 유래 추출물을 포함하는 혈당 강하용 조성물 | |
Khan et al. | Cardamom Safety | |
CN115737777B (zh) | 一种复方解酒中药组合物及其制备方法 | |
CN107375693A (zh) | 一种增强机体免疫力的中药保健品及其制备方法 | |
KR101154182B1 (ko) | 방광과체질에 처방되는 변비개선용 천연음료 조성물 | |
KR101391648B1 (ko) | 항비만 조성물 | |
Kamble Santosh et al. | TAMBULA-SEVANA AS A HEALTHY DAILY REGIMEN: AN AYURVEDA OVERVIEW | |
Damle et al. | A case report on the use of Ayurveda in the treatment of Iron Deficiency Anaemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220830 |
|
WW01 | Invention patent application withdrawn after publication |